Why Palantir’s Future Just Got a Massive Boost

Palantir (PLTR) just landed two major new contracts—one in commercial healthcare and another in defense—sparking bullish ratings from analysts and attracting attention from congressional investors. Price targets continue climbing, but longtime Palantir bull, MarketBeat’s Chris Markoch, sees reasons for caution in the short term despite tremendous long-term potential. In this interview, Chris details exactly why Palantir’s latest deals are so significant, addresses concerns around insider selling, and reveals why short-term traders might want to hold off—while patient, long-term investors could reap massive rewards. If you’re serious about Palantir’s future, this is a must-watch conversation. 📊 Download MarketBeat’s FREE Report on the 10 Best AI Stocks for 2025: http://marketbeat.link/10BestAI 📲 Text ’YouTube’ to 68285 for FREE SMS breaking news alerts on top stocks. ✨ Get MarketBeat All Access FREE for 30 Days: 👉 https://www.marketbeat.com/subscribe/all-access/?utm_source=YouTube&RegistrationCode=YouTube #StocksToBuy #Palantir #PLTR #stockpicks #investingtips #marketbeat #ChrisMarkoch #investingvideos #defensestocks #techstocks #AIstocks #growthstocks #stockanalysis